Literature DB >> 28214948

Reduced anticoagulation variability in patients on warfarin monitored with Fiix-prothrombin time associates with reduced thromboembolism: The Fiix-trial.

Alma Rut Oskarsdóttir1, Brynja R Gudmundsdottir1, Olafur S Indridason1, Sigrun H Lund2, David O Arnar1, Einar S Bjornsson1,2, Magnus K Magnusson1,2, Hulda M Jensdottir1, Brynjar Vidarsson1, Charles W Francis3, Pall T Onundarson4,5.   

Abstract

Fiix-prothrombin time (Fiix-PT) differs from traditional PT in being affected by reduced factor (F) II or FX only. In the randomized controlled Fiix-trial, patients on warfarin monitored with Fiix-PT (Fiix-warfarin patients) had fewer thromboembolisms (TE), similar major bleeding (MB) and more stable anticoagulation than patients monitored with PT (PT-warfarin patients). In the current Fiix-trial report we analyzed how reduced anticoagulation variability during Fiix-PT monitoring was reflected in patients with TE or bleeding. Data from 1143 randomized patients was used. We analyzed the groups for anticoagulation intensity (time within target range; TTR), international normalized ratio (INR) variability (variance growth rate B1; VGR) and dose adjustment frequency. We assessed how these parameters associated with clinically relevant vascular events (CRVE), ie TE or MB or clinically relevant non-MB. TTR was highest in Fiix-warfarin patients without CRVE (median 82%;IQR 72-91) and lowest in PT-warfarin patients with TE (62%;56-81). VGR was lowest in Fiix-warfarin patients without CRVE (median VGR B1 0.17; 95% CI 0.08-0.38) and with TE (0.20;0.07-0.26) and highest in PT-warfarin patients with TE (0.50;0.27-0.90) or MB (0.59;0.07-1.36). The mean annual dose adjustment frequency was lowest in Fiix-warfarin patients with TE (mean 5.4;95% CI 3.9-7.3) and without CRVE (mean 6.0; 5.8-6.2) and highest in PT-warfarin patients with TE (14.2;12.2-16.3). Frequent dose changes predicted MB in both study arms. Compared to patients monitored with PT, high anticoagulation stability in Fiix-warfarin patients coincided with their low TE rate. Those with bleeding had high variability irrespective of monitoring method. Thus, although further improvements are needed to reduce bleeding, stabilization of anticoagulation by Fiix-PT monitoring associates with reduced TE.

Entities:  

Keywords:  Fiix; INR; Monitoring; Oral anticoagulants; Prothrombin time; Warfarin

Mesh:

Substances:

Year:  2017        PMID: 28214948     DOI: 10.1007/s11239-017-1482-4

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  37 in total

1.  Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin.

Authors:  Elizabeth Sconce; Peter Avery; Hilary Wynne; Farhad Kamali
Journal:  Blood       Date:  2006-11-16       Impact factor: 22.113

2.  Differences among western European countries in anticoagulation management of atrial fibrillation. Data from the PREFER IN AF registry.

Authors:  Jean-Yves Le Heuzey; Bettina Ammentorp; Harald Darius; Raffaele De Caterina; Richard John Schilling; Josef Schmitt; José Luis Zamorano; Paulus Kirchhof
Journal:  Thromb Haemost       Date:  2014-03-20       Impact factor: 5.249

3.  Multicentre randomised study of computerised anticoagulant dosage. European Concerted Action on Anticoagulation.

Authors:  L Poller; C R Shiach; P K MacCallum; A M Johansen; A M Münster; A Magalhães; J Jespersen
Journal:  Lancet       Date:  1998-11-07       Impact factor: 79.321

4.  Randomized prospective trial comparing the native prothrombin antigen with the prothrombin time for monitoring oral anticoagulant therapy.

Authors:  B Furie; C F Diuguid; M Jacobs; D L Diuguid; B C Furie
Journal:  Blood       Date:  1990-01-15       Impact factor: 22.113

5.  Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation.

Authors:  Elizabeth Sconce; Tayyaba Khan; Jennifer Mason; Faye Noble; Hilary Wynne; Farhad Kamali
Journal:  Thromb Haemost       Date:  2005-05       Impact factor: 5.249

6.  A pharmacogenetic versus a clinical algorithm for warfarin dosing.

Authors:  Stephen E Kimmel; Benjamin French; Scott E Kasner; Julie A Johnson; Jeffrey L Anderson; Brian F Gage; Yves D Rosenberg; Charles S Eby; Rosemary A Madigan; Robert B McBane; Sherif Z Abdel-Rahman; Scott M Stevens; Steven Yale; Emile R Mohler; Margaret C Fang; Vinay Shah; Richard B Horenstein; Nita A Limdi; James A S Muldowney; Jaspal Gujral; Patrice Delafontaine; Robert J Desnick; Thomas L Ortel; Henny H Billett; Robert C Pendleton; Nancy L Geller; Jonathan L Halperin; Samuel Z Goldhaber; Michael D Caldwell; Robert M Califf; Jonas H Ellenberg
Journal:  N Engl J Med       Date:  2013-11-19       Impact factor: 91.245

7.  Critical role of factors II and X during coumarin anticoagulation and their combined measurement with a new Fiix-prothrombin time.

Authors:  Brynja R Gudmundsdottir; Charles W Francis; Alexia M Bjornsdottir; Moa Nellbring; Pall T Onundarson
Journal:  Thromb Res       Date:  2012-01-04       Impact factor: 3.944

8.  Risk factors for nonadherence to warfarin: results from the IN-RANGE study.

Authors:  Alec B Platt; A Russell Localio; Colleen M Brensinger; Dean G Cruess; Jason D Christie; Robert Gross; Catherine S Parker; Maureen Price; Joshua P Metlay; Abigail Cohen; Craig W Newcomb; Brian L Strom; Mitchell S Laskin; Stephen E Kimmel
Journal:  Pharmacoepidemiol Drug Saf       Date:  2008-09       Impact factor: 2.890

9.  Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors.

Authors:  A Zivelin; L V Rao; S I Rapaport
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

10.  A method to determine the optimal intensity of oral anticoagulant therapy.

Authors:  F R Rosendaal; S C Cannegieter; F J van der Meer; E Briët
Journal:  Thromb Haemost       Date:  1993-03-01       Impact factor: 5.249

View more
  3 in total

1.  The need for an adapted initiation nomogram during Fiix prothrombin time monitoring of warfarin.

Authors:  Pall T Onundarson; Brynja R Gudmundsdottir
Journal:  J Thromb Thrombolysis       Date:  2019-11       Impact factor: 2.300

2.  Ignoring instead of chasing after coagulation factor VII during warfarin management: an interrupted time series study.

Authors:  Alma R Oskarsdottir; Brynja R Gudmundsdottir; Hulda M Jensdottir; Bjorn Flygenring; Ragnar Palsson; Pall T Onundarson
Journal:  Blood       Date:  2021-05-20       Impact factor: 22.113

3.  Impact of VKORC1, CYP2C9, CYP1A2, UGT1A1, and GGCX polymorphisms on warfarin maintenance dose: Exploring a new algorithm in South Chinese patients accept mechanical heart valve replacement.

Authors:  Jin Li; Tao Chen; Fangfang Jie; Haiyan Xiang; Li Huang; Hongfa Jiang; Fei Lu; Shuqiang Zhu; Lidong Wu; Yanhua Tang
Journal:  Medicine (Baltimore)       Date:  2022-07-22       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.